TW202334201A - 抗Ｔａｕ抗體之組成物、劑型及方法 - Google Patents

抗Ｔａｕ抗體之組成物、劑型及方法 Download PDF

Info

Publication number
TW202334201A
TW202334201A TW111142044A TW111142044A TW202334201A TW 202334201 A TW202334201 A TW 202334201A TW 111142044 A TW111142044 A TW 111142044A TW 111142044 A TW111142044 A TW 111142044A TW 202334201 A TW202334201 A TW 202334201A
Authority
TW
Taiwan
Prior art keywords
antibody
tau
tauopathy
dose
treating
Prior art date
Application number
TW111142044A
Other languages
English (en)
Chinese (zh)
Inventor
拉里薩 瑞德曼
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202334201A publication Critical patent/TW202334201A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111142044A 2021-11-03 2022-11-03 抗Ｔａｕ抗體之組成物、劑型及方法 TW202334201A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163275045P 2021-11-03 2021-11-03
US63/275,045 2021-11-03
US202163290278P 2021-12-16 2021-12-16
US63/290,278 2021-12-16
US202263316582P 2022-03-04 2022-03-04
US202263316616P 2022-03-04 2022-03-04
US63/316,616 2022-03-04
US63/316,582 2022-03-04

Publications (1)

Publication Number Publication Date
TW202334201A true TW202334201A (zh) 2023-09-01

Family

ID=84360026

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142044A TW202334201A (zh) 2021-11-03 2022-11-03 抗Ｔａｕ抗體之組成物、劑型及方法

Country Status (8)

Country Link
EP (1) EP4426336A1 (https=)
JP (1) JP2024540226A (https=)
KR (1) KR20240118915A (https=)
AU (1) AU2022381556A1 (https=)
CA (1) CA3237660A1 (https=)
MX (1) MX2024005430A (https=)
TW (1) TW202334201A (https=)
WO (1) WO2023079485A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
CN117946264B (zh) * 2024-03-21 2024-06-04 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其应用
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074420A2 (en) * 2013-11-27 2016-10-05 Ipierian, Inc. Methods of treating a tauopathy
MA48595A (fr) * 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
EP3697814A1 (en) 2017-10-16 2020-08-26 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Also Published As

Publication number Publication date
AU2022381556A1 (en) 2024-05-02
CA3237660A1 (en) 2023-05-11
EP4426336A1 (en) 2024-09-11
JP2024540226A (ja) 2024-10-31
KR20240118915A (ko) 2024-08-05
WO2023079485A1 (en) 2023-05-11
MX2024005430A (es) 2024-05-21

Similar Documents

Publication Publication Date Title
TW202334201A (zh) 抗Ｔａｕ抗體之組成物、劑型及方法
WO2023095852A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
WO2023111618A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
CN118215497A (zh) 抗tau抗体组合物、剂型和方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
US20190247503A1 (en) Methods for treating relapsing forms of multiple sclerosis